Jazeta (Sitagliptin Hydrochloride)

Sitagliptin Hydrochloride, the active ingredient in Jazeta, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is used to improve blood glucose control in adults with type 2 diabetes mellitus. GNH USA supplies Jazeta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jazeta is a DPP‑4 inhibitor indicated for the management of type 2 diabetes mellitus, acting on the incretin pathway to improve glycaemic control.

Type 2 diabetes mellitus: improves fasting and post‑prandial blood glucose levels as monotherapy or in combination with other antidiabetic agents. Adjunct therapy for type 2 diabetes: can be combined with metformin, sulfonylureas or insulin to achieve target HbA1c. Glycaemic control maintenance: helps sustain long‑term glucose regulation when diet and exercise alone are insufficient.

Common Side Effects: - Nasopharyngitis: mild upper‑respiratory tract infection symptoms. - Headache: transient mild to moderate headache. - Gastrointestinal upset: occasional nausea or abdominal discomfort. - Dizziness: occasional light‑headed sensation.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe hypersensitivity: rash, angioedema, or anaphylaxis. - Bullous pemphigoid: rare skin blistering disorder. - Severe joint pain: unexplained arthralgia that may indicate autoimmune reaction.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for adverse events. - Renal function: assess baseline creatinine clearance and adjust dose if necessary. - Hypersensitivity: discontinue immediately if signs of allergic reaction appear. - Pancreatitis: advise patients to report persistent severe abdominal pain. - Cardiovascular status: use cautiously in patients with heart failure. - Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

Sitagliptin may interact with several concomitant medicines, requiring clinical awareness.

Major Interactions (Avoid): - Sulfonylureas or insulin: increased risk of hypoglycaemia when combined. - Rifampin: may reduce sitagliptin plasma concentrations, lowering efficacy.

Moderate Interactions (Monitor Closely): - Diuretics: may affect glucose homeostasis, requiring monitoring. - ACE inhibitors or ARBs: watch renal function and electrolytes. - Warfarin: potential alteration of INR, necessitating regular coagulation checks.